✦ LIBER ✦

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

✍ Scribed by Eric J. Lawitz; Daniel Gruener; John M. Hill; Thomas Marbury; Lisa Moorehead; Anita Mathias; Guofeng Cheng; John O. Link; Kelly A. Wong; Hongmei Mo; John G. McHutchison; Diana M. Brainard

Book ID: 116652701
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 830 KB
Volume: 57
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2011.12.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prevalence of hepatitis C virus variants

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b

✍ Fumitaka Suzuki; Hitomi Sezaki; Norio Akuta; Yoshiyuki Suzuki; Yuya Seko; Yusuke 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 156 KB

A Phase II, Randomized, Double-Blind, Pl

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in Naïve Patients With Chronic Hepatitis C Genotype 1 Infection: Final Report

✍ Bruce R. Bacon; Mitchell L. Shiffman; Joseph K. Lim; Arthur Berman; Vinod K. Rus 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Multiple ascending dose study of BMS-790

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

✍ Richard E. Nettles; Min Gao; Marc Bifano; Ellen Chung; Anna Persson; Thomas C. M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB

Abbreviations: AE, adverse event; AUC, area under the plasma concentration time curve; AUC (TAU) , AUC over 12-hour dosing interval for 30 mg twice daily; C min , minimum observed plasma concentration; C max , maximum observed plasma concentration; C trough , trough concentrations; CLT/F, apparent t

Impact of high-dose peginterferon alfa-2

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial

✍ Stuart K. Roberts; Martin D. Weltman; Darrell H. G. Crawford; Geoffrey W. McCaug 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 2 views

This study tested the hypothesis that high-dose peginterferon alfa-2a (PEG-IFNalpha-2a) for the first 12 weeks would increase early and sustained virological response (SVR) rates in patients with chronic hepatitis C genotype 1. Eight hundred ninety-six patients were randomized 1:1 to 360 microg (n =

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection

✍ Peter Ferenci; Elisabeth Formann; Hermann Laferl; Michael Gschwantler; Franz Hac 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Treatment of chronic hepatitis C patient

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study

✍ Nicole Forestier; Dominique Larrey; Dominique Guyader; Patrick Marcellin; Régine 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 651 KB